company background image
CUV logo

Clinuvel Pharmaceuticals ASX:CUV Stock Report

Last Price

AU$14.70

Market Cap

AU$721.7m

7D

-1.6%

1Y

-22.1%

Updated

13 Jun, 2024

Data

Company Financials +

Clinuvel Pharmaceuticals Limited

ASX:CUV Stock Report

Market Cap: AU$721.7m

CUV Stock Overview

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

CUV fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Clinuvel Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clinuvel Pharmaceuticals
Historical stock prices
Current Share PriceAU$14.70
52 Week HighAU$21.45
52 Week LowAU$12.96
Beta0.92
1 Month Change-5.89%
3 Month Change-2.33%
1 Year Change-22.06%
3 Year Change-45.94%
5 Year Change-61.77%
Change since IPO1,370.00%

Recent News & Updates

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jun 27
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

May 09
Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Mar 24
Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18
An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30
Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27
Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14
Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03
This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23
A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10
With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06
Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27
Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20
What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01
Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14
Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28
We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21
What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Shareholder Returns

CUVAU BiotechsAU Market
7D-1.6%-1.5%-0.7%
1Y-22.1%-0.5%8.2%

Return vs Industry: CUV underperformed the Australian Biotechs industry which returned -0.5% over the past year.

Return vs Market: CUV underperformed the Australian Market which returned 8.2% over the past year.

Price Volatility

Is CUV's price volatile compared to industry and market?
CUV volatility
CUV Average Weekly Movement6.8%
Biotechs Industry Average Movement11.4%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market3.2%

Stable Share Price: CUV has not had significant price volatility in the past 3 months.

Volatility Over Time: CUV's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aPhilippe Wolgenwww.clinuvel.com

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.

Clinuvel Pharmaceuticals Limited Fundamentals Summary

How do Clinuvel Pharmaceuticals's earnings and revenue compare to its market cap?
CUV fundamental statistics
Market capAU$721.69m
Earnings (TTM)AU$30.15m
Revenue (TTM)AU$81.76m

24.4x

P/E Ratio

9.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CUV income statement (TTM)
RevenueAU$81.76m
Cost of RevenueAU$6.70m
Gross ProfitAU$75.06m
Other ExpensesAU$44.90m
EarningsAU$30.15m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.60
Gross Margin91.80%
Net Profit Margin36.88%
Debt/Equity Ratio0%

How did CUV perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

8%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.